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Kawasaki	  Disease	  (KD)	  is	  an	  idiopathic,	  
mul0system	  disorder.	  It	  is	  characterized	  
by	  vasculi0s	  of	  the	  arteries,	  capillaries,	  
and	  veins	  and	  typically	  affects	  children	  5	  
years	  old	  or	  younger	  (Luban,	  Wong,	  
Lobo,	  Pary,	  &	  Duke,	  2015).	  This	  
inflamma0on	  of	  the	  blood	  vessels	  
makes	  Kawasaki	  disease	  the	  leading	  
cause	  of	  acquired	  heart	  disease	  in	  
children,	  with	  20%	  of	  those	  affected	  
developing	  coronary	  artery	  aneurysms,	  
cardiac	  arrhythmias,	  and	  heart	  failure	  
(Luban	  et	  al.,	  2015).	  KD	  occurs	  in	  all	  
races,	  but	  is	  predominately	  seen	  in	  male	  
children	  of	  Japanese	  decent.	  Diagnosis	  
is	  based	  on	  criteria	  including	  presence	  
of	  fever	  for	  5	  days,	  bilateral	  
conjunc0vi0s,	  erythema	  of	  the	  lips	  and	  
oral	  mucosa,	  changes	  in	  extremi0es,	  
rash,	  and	  cervical	  lymphadenopathy	  
(Sehgal,	  Chen,	  &	  Ang,	  2015).	  Treatment	  
of	  KD	  typically	  involves	  high-­‐dose	  
aspirin	  and	  intravenous	  
immunoglobulin	  (IVIG)	  while	  
hospitalized	  and	  low-­‐dose	  aspirin	  un0l	  
inflammatory	  markers	  decrease	  (Sehgal	  
et	  al.,	  2015).	  	  
	  O1erbein	  University,	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Underlying	  Pathophysiology	  Background	  
Signs	  &	  Symptoms	  
There	  is	  no	  specific	  diagnos0c	  
test	  available	  for	  KD	  and	  diagnosis	  is	  
currently	  based	  on	  clinical	  criteria	  
adopted	  by	  the	  American	  Heart	  
Associa0on.	  At	  least	  5	  of	  the	  following	  
symptoms	  must	  be	  seen:	  
	  
•  Fever	  persis0ng	  greater	  than	  5	  days	  
•  Changes	  in	  extremi0es,	  including	  
indura0ve	  angioedema	  and	  
desquama0on	  
•  Polymorphous	  exanthema	  (diffuse	  
rash)	  
•  Bilateral	  bulbar	  conjunc0val	  injec0on	  
without	  exudate	  
•  Changes	  to	  the	  lips	  and	  oral	  cavity,	  
including	  pharyngeal	  injec0on,	  dry	  
fissured	  lips,	  and/or	  strawberry	  
tongue	  
•  Acute	  nonpurulent	  cervical	  
lymphadenopathy	  
•  Elevated	  inflammatory	  markers	  (C-­‐
reac0ve	  protein	  and	  erythrocyte	  
sedimenta0on	  rate)	  (Jamieson	  &	  
Singh-­‐Grewal,	  2013)	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•  A	  specific	  agent	  has	  not	  been	  iden0fied,	  however	  KD	  is	  thought	  
to	  be	  triggered	  by	  an	  infec0ous	  agent	  that	  causes	  an	  immune	  
response	  in	  a	  gene0cally	  suscep0ble	  host	  
•  An	  infec0ous	  e0ology	  is	  also	  supported	  by	  the	  fact	  that	  KD	  is	  
seen	  predominantly	  in	  the	  winter	  and	  spring,	  found	  mostly	  in	  
children,	  and	  is	  self-­‐limi0ng	  similar	  to	  other	  viral	  diseases	  
•  The	  vasculi0s	  of	  KD	  reveals	  an	  infiltra0on	  of	  macrophages,	  
neutrophils,	  and	  CD8	  T	  cells	  (Dimitriades,	  Brown,	  &	  Gedalia,	  
2014)	  
•  Pro-­‐inflammatory	  cytokines	  that	  are	  released	  are	  directly	  related	  
to	  the	  fever,	  mucosal	  involvement,	  and	  desquama0on	  seen	  in	  KD	  
(Dimitriades,	  Brown,	  &	  Gedalia,	  2014)	  
•  These	  cytokines	  then	  target	  the	  endothelial	  cells	  and	  result	  in	  a	  
cascade	  of	  events	  that	  cause	  vascular	  damage.	  In	  severely	  
affected	  vessels,	  the	  media	  develops	  inflamma0on	  with	  necrosis	  
of	  smooth	  muscle	  cells	  (Medscape,	  2015)	  
•  Over	  the	  next	  few	  weeks	  to	  months,	  the	  ac0ve	  inflammatory	  
cells	  are	  replaced	  by	  fibroblasts	  and	  monocytes,	  and	  fibrous	  
connec0ve	  0ssue	  begins	  to	  form	  within	  the	  vessel	  wall.	  	  The	  
vessel	  wall	  eventually	  becomes	  narrowed	  or	  occluded	  owing	  to	  
stenosis	  or	  a	  thrombus.	  Cardiovascular	  death	  may	  occur	  from	  a	  
myocardial	  infarc0on	  secondary	  to	  thrombosis	  of	  a	  coronary	  




KD	  has	  a	  higher	  incidence	  in	  Japanese-­‐Americans,	  as	  well	  as	  an	  
increased	  risk	  in	  the	  siblings	  of	  those	  affected.	  This	  suggests	  that	  
host	  gene0c	  factors	  are	  important	  in	  determining	  the	  abnormal	  
immunological	  response	  to	  the	  infec0ous	  triggers.	  KD	  also	  
predominantly	  affects	  young	  children;	  80%	  of	  cases	  occur	  
between	  the	  ages	  of	  6	  months	  and	  4	  years	  and	  has	  a	  male	  
predominance	  (Yim,	  Cur0s,	  Cheung,	  &	  Burgner,	  2013).	  KD	  also	  
has	  a	  peak	  incidence	  in	  the	  winter	  and	  spring.	  Over	  0me,	  a	  rising	  
incidence	  has	  been	  observed	  worldwide,	  possibly	  due	  to	  
heightened	  awareness	  and	  recogni0on	  of	  the	  disease	  (Jamieson	  
&	  Singh-­‐Grewal,	  2013).	  	  
Implica=ons	  for	  Nursing	  Care	  
	  Treatment	  for	  KD	  includes	  administra0on	  of	  intravenous	  immunoglobulin	  and	  aspirin.	  	  
•  Intravenous	  immunoglobulin:	  The	  mechanism	  of	  ac0on	  of	  IVIG	  
remains	  unknown,	  however	  a	  single	  dose	  of	  2	  g/kg,	  given	  over	  
10–12	  hours,	  paired	  together	  with	  aspirin	  within	  10	  days	  of	  
fever	  onset	  results	  in	  rapid	  resolu0on	  of	  clinical	  symptoms	  in	  
80–90%	  of	  pa0ents	  and	  has	  been	  shown	  to	  reduce	  the	  risk	  of	  
coronary	  disease	  from	  20–25%	  to	  about	  2–4%	  (Patel	  &	  
Shulman,	  2015).	  	  
•  Aspirin:	  An0-­‐inflammatory	  doses	  of	  80–100	  mg/kg/day	  is	  used	  
in	  the	  acute	  phase,	  followed	  by	  lower	  an0platelet	  doses	  of	  3–	  
5	  mg/kg/day	  aler	  defervescence	  (Patel	  &	  Shulman,	  2015).	  	  
•  Other	  therapies:	  In	  pa0ents	  who	  do	  not	  respond	  to	  primary	  
therapy	  with	  IVIG	  and	  aspirin,	  the	  best	  management	  approach	  
remains	  unclear.	  Addi0onal	  therapy	  op0ons	  include	  a	  second	  
dose	  of	  IVIG,	  pulse	  prednisolone	  therapy,	  and	  infliximab.	  Most	  
recently,	  the	  use	  of	  calcineurin	  inhibitors,	  par0cularly	  cyclo-­‐	  
sporine,	  has	  been	  used	  for	  treatment	  of	  pa0ents	  who	  failed	  
mul0ple	  other	  therapies.	  Because	  the	  clinical	  symptoms	  of	  KD	  
are	  self-­‐limited,	  it	  is	  difficult	  to	  determine	  whether	  case	  
reports	  of	  pa0ents	  who	  apparently	  responded	  to	  rescue	  
therapies	  represent	  true	  clinical	  responses	  (Rowley,	  2012).	  	  
Conclusion	  
Kawasaki	  Disease	  is	  the	  most	  common	  cause	  of	  acquired	  heart	  
disease	  for	  children	  in	  the	  United	  States.	  Primary	  health	  providers	  
play	  an	  important	  role	  in	  the	  early	  detec0on	  and	  diagnosis	  of	  
children	  with	  KD.	  Timely	  diagnosis	  and	  administra0on	  of	  
treatments	  has	  been	  shown	  to	  improve	  outcomes	  and	  reduce	  the	  
risk	  of	  cardiac	  complica0ons.	  	  
Above	  image	  showcases	  classic	  signs	  and	  symptoms	  of	  Kawasaki	  Disease	  in	  Children.	  Image	  
retrieved	  from:	  hep://kdfounda0on.org/index.php	  
	  
Above	  image	  model	  of	  disease	  pathogenesis.	  Retrieved	  from	  hep://www.medscape.com/
viewar0cle/726901_4	  
Significance	  of	  Pathophysiology	  
•  The	  period	  of	  the	  greatest	  vascular	  damage	  is	  due	  to	  the	  
increase	  in	  the	  serum	  platelet	  count,	  and	  this	  is	  the	  point	  of	  the	  
illness	  when	  the	  risk	  of	  death	  is	  most	  significant	  (Medscape,	  
2015).	  
•  	  Also,	  pathologic	  findings	  should	  change	  the	  way	  prac00oners	  
think	  about	  "regression"	  of	  coronary	  artery	  aneurysms	  aler	  
KD.	  The	  lumen	  of	  saccular	  aneurysms	  seen	  in	  some	  pa0ents	  
with	  KD	  becomes	  smaller	  over	  0me	  because	  of	  deposi0on	  of	  
sequen0al	  layers	  of	  thrombi;	  this	  decrease	  in	  lumen	  size	  does	  
not	  necessarily	  represent	  "healing"	  of	  the	  arterial	  wall	  (Rowley,	  
2012).	  
•  Decrease	  in	  size	  of	  the	  lumen	  of	  fusiform	  aneurysms	  may	  result	  
from	  thrombus	  forma0on	  or	  from	  LMP	  stenosis.	  Although	  it	  is	  
unlikely	  that	  aneurysmal	  arteries	  return	  to	  normal,	  
nonaneurysmal	  arteries	  that	  develop	  mild	  dila0on	  as	  a	  result	  of	  
edema	  and	  minimal	  inflammatory	  infiltrate	  likely	  can	  return	  to	  
normal	  or	  near	  normal	  (Rowley,	  2012).	  
•  	  Understanding	  the	  underlying	  pathophysiology	  leads	  to	  a	  
beeer	  understanding	  of	  the	  poten0al	  dangers	  facing	  KD	  
pa0ents	  with	  severe	  coronary	  artery	  abnormali0es	  over	  0me	  
(Rowley,	  2012).	  
•  Studies	  show	  that	  risk	  factors	  for	  the	  development	  of	  coronary	  
artery	  abnormali0es	  in	  pa0ents	  with	  KD	  and	  prevalence	  of	  
coronary	  disease	  were	  lower	  in	  children	  who	  were	  treated	  
before	  the	  filh	  illness	  day	  compared	  with	  aler	  the	  filh	  illness	  
day	  was	  reported	  (Rowley,	  2012).	  	  
